Güçbey Türker Özge, Kalkan Çağdaş, Bilican Gülden, Asfuroğlu Kalkan Emra, Atay Ali, Ateş İhsan, Soykan İrfan
Department of Internal Medicine, Ankara City Hospital, University of Health Sciences, Ankara 06800, Turkey.
Department of Gastroenterology, Ankara City Hospital, University of Health Sciences, Ankara 06800, Turkey.
J Clin Med. 2025 Jul 20;14(14):5143. doi: 10.3390/jcm14145143.
: Autoimmune liver diseases (ALDs) are a diverse group of chronic inflammatory disorders. Individuals with a history of one autoimmune disease (AD) are at a substantially increased risk of developing additional autoimmune conditions. Polyautoimmunity has increasingly been recognized as a factor associated with a more complex disease course and poorer long-term outcomes. : This retrospective, cross-sectional observational study reviewed medical records of patients diagnosed with ALDs who had been admitted to the gastroenterology clinic. : A total of 457 patients with ALDs were included. Polyautoimmunity was present in 194 patients (42.5%), and multiple autoimmune syndrome (MAS) was diagnosed in 26 of these patients (5.7%). Serological comparisons revealed that antinuclear antibody (ANA) positivity was significantly more common in the polyautoimmunity group. Only 22.2% of the patients with polyautoimmunity were ANA-negative, compared with 52.9% in those without. An ROC curve analysis was conducted to assess the predictive value of clinical and laboratory variables for polyautoimmunity. Among all the tested parameters, ANA positivity (>+2) had the strongest predictive value (AUC: 0.724). A disease duration longer than 6.5 years followed, with a moderate discriminative capacity (AUC: 0.677). Additionally, lower albumin levels (<3.0 g/dL) and elevated erythrocyte sedimentation rates (ESRs) (>29.5 mm/h) were significantly associated with polyautoimmunity. : In our cohort, 42.5% of patients had at least one additional autoimmune disorder, highlighting the need for a systemic and comprehensive approach to patient care. Simple and accessible markers-such as ANA titers, disease duration, albumin levels, and ESRs-may help to identify patients at greater risk.
自身免疫性肝病(ALD)是一组多样的慢性炎症性疾病。有自身免疫性疾病(AD)病史的个体发生其他自身免疫性疾病的风险大幅增加。多自身免疫性越来越被认为是与更复杂的病程和更差的长期预后相关的一个因素。:这项回顾性横断面观察性研究回顾了入住胃肠病科门诊的ALD确诊患者的病历。:总共纳入了457例ALD患者。194例患者(42.5%)存在多自身免疫性,其中26例患者(5.7%)被诊断为多重自身免疫综合征(MAS)。血清学比较显示,抗核抗体(ANA)阳性在多自身免疫性组中显著更常见。多自身免疫性患者中只有22.2%为ANA阴性,而无多自身免疫性的患者中这一比例为52.9%。进行了ROC曲线分析以评估临床和实验室变量对多自身免疫性的预测价值。在所有测试参数中,ANA阳性(> +2)具有最强的预测价值(AUC:0.724)。其次是疾病持续时间超过6.5年,具有中等判别能力(AUC:0.677)。此外,较低的白蛋白水平(<3.0 g/dL)和升高的红细胞沉降率(ESR)(>29.5 mm/h)与多自身免疫性显著相关。:在我们的队列中,42.5%的患者至少有一种额外的自身免疫性疾病,这突出了对患者护理采取系统和全面方法的必要性。简单且易于获取的标志物,如ANA滴度、疾病持续时间、白蛋白水平和ESR,可能有助于识别风险更高的患者。